Form 8-K - Current report:
SEC Accession No. 0001213900-25-080110
Filing Date
2025-08-25
Accepted
2025-08-25 08:00:35
Documents
14
Period of Report
2025-08-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0254361-8k_immucell.htm   iXBRL 8-K 27384
2 ALLONGE TO AND AMENDMENT OF LINE OF CREDIT LOAN BETWEEN THE COMPANY AND MAINE CO ea025436101ex10-1_immucell.htm EX-10.1 6138
3 GRAPHIC ex10-1_001.jpg GRAPHIC 4649
  Complete submission text file 0001213900-25-080110.txt   205557

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20250820.xsd EX-101.SCH 3014
5 XBRL LABEL FILE iccc-20250820_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE iccc-20250820_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0254361-8k_immucell_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 251247938
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)